How effective is Rucaparib in treating ovarian cancer?

Rucaparib (Rucaparib) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the United States and the European Union for the treatment of adult patients with BRCA-mutated ovarian cancer who have received two or more types of chemotherapy, and for the maintenance treatment of adult patients with relapsed or relapsed ovarian cancer who have had a complete or partial response to platinum-based chemotherapy.

Based on an analysis of patients in two phase II clinical trials, rucaparib showed clinical activity as a third-line (or later) treatment for BRCA-mutated ovarian cancer, with a confirmed objective response rate of 54% in patients treated with rucaparib. Additionally, as demonstrated in the randomized, placebo-controlled, phase III ARIEL3 trial, rucaparib significantly improved progression-free survival when used as maintenance therapy in patients with platinum-sensitive ovarian cancer. Rucaparib was acceptably tolerated in clinical trials in women with ovarian cancer. Common adverse events can generally be managed with dose adjustment and/or supportive care. Currently available data suggest that rucaparib is a useful addition to the options available to clinicians for the treatment of advanced ovarian cancer in both the treatment and maintenance settings.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).